Shanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; Honghu, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR'obot, a Mona Lisa robotic transperineal prostate biopsy system. The company also provides spine surgical robots; trans-bronchial surgical robots for trans-bronchial diagnosis and treatment; TAVR surgical robots for heart valve replacement surgery; and automated needle targeting robotics systems for percutaneous lung biopsy and percutaneous nephrolithotomy. Shanghai Microport Medbot (Group) Co., Ltd. was founded in 2014 and is based in Shanghai, China. Shanghai Microport Medbot (Group) Co., Ltd. operates as a subsidiary of MicroPort Scientific Corporation.

2252

HKSE:2252

Shanghai MicroPort MedBot (Group) Co., Ltd.

Last Close

7.19

30/08 08:08

Market Cap

8.19B

Beta: -

Volume Today

1.14M

Avg: 1.86M

PE Ratio

−7.68

PFCF: −8.14

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics